A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects
調査の概要
状態
条件
詳細な説明
This is a randomized (the study medication is assigned by chance), open-label (physicians and participants know the identity of the assigned treatment), single-center, single-dose, 3-treatment, 3-way crossover (the same medications are provided to all participants but in different sequence) study of canagliflozin (CANA) and metformin extended release (MET XR) combined in one tablet, in comparison with tablets containing the individual components. Two Fixed Dose Combinations (FDCs) will be evaluated during the study (two types of tablets).
The tablets will be of the same strength (150 mg CANA/1,000 mg MET XR) and will be compared with equal doses of the individual drugs: canagliflozin (1 x 300 mg tablet) and metformin XR (4 x 500 mg tablets). Thus, there will be 3 treatment periods in the study: Treatment A: "Reference" treatment of individual components administered concurrently; Treatment B: CANA/MET XR FDC, formulation 1; and Treatment C: CANA/MET XR FDC, formulation 2. Approximately 42 healthy adult participants will be randomly assigned to 1 of the 3 treatments groups, and then each group will receive all three treatments in different sequences (3-way crossover). The study will consist of 3 phases: a Screening Phase of approximately 3 weeks, an Open-Label Treatment Phase consisting of 3 single-dose Treatment Periods of 5 days each separated by a washout period of 10 to 14 days and a Follow-up Phase occurring 7 to 10 days after the last study-related procedure of Treatment Period 3. The total duration of the study will be about 70 days for each participant.
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Arizona
-
Tempe、Arizona、アメリカ
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Must sign an informed consent document indicating they understand the purpose of the study and procedures
- Must have a body mass index (BMI) of between 18 and 30 kg/m2, inclusive
- Must have a body weight of not less than 50 kg - Must have a blood pressure between 90 and 140 mmHg inclusive, systolic, and no higher than 90 mmHg diastolic at screening
- Must have normal renal function and no evidence of kidney damage (including abnormalities in blood or urine tests)
Exclusion Criteria:
- History of or current clinically significant medical illness
- Use of any prescription or nonprescription medication (including vitamins and herbal supplements)
- History of clinically significant allergies, especially known hypersensitivity or intolerance to drugs or lactose
- Known allergy to heparin or history of heparin induced thrombocytopenia
- Donated blood or blood products or had substantial loss of blood within 3 months before screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:クロスオーバー割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:Treatment A
Each participant will receive a single dose of 1 tablet of canagliflozin (CANA), 300 mg, and 4 tablets of metformin extended release (MET XR), 500 mg each, administered together under fed conditions.
|
1錠あたり300mgのカナグリフロジン(CANA)を含有しており、経口(口から)摂取できます。
他の名前:
各錠剤には、メトホルミン徐放性 (MET XR) 500 mg が含まれており、経口で摂取できます。
他の名前:
|
実験的:治療B
各参加者は、摂食条件下で、CANA/MET XR FDC、製剤 1 の 2 錠を単回投与されます。
|
Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
|
実験的:治療C
各参加者は、摂食条件下で、CANA/MET XR FDC、製剤 2 の 2 錠を単回投与されます。
|
Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Plasma concentration of canagliflozin following administration of a single dose of study drug
時間枠:Predose, (before tablet intake) up to 72 hours after dose
|
Plasma concentrations of canagliflozin are used to evaluate how long canagliflozin stays in the body.
|
Predose, (before tablet intake) up to 72 hours after dose
|
Plasma concentration of metformin following administration of a single dose of study drug
時間枠:Predose, up to 36 hours after dose
|
Plasma concentrations of metformin are used to evaluate how long metformin stays in the body.
|
Predose, up to 36 hours after dose
|
二次結果の測定
結果測定 |
時間枠 |
---|---|
Percentage of participants with adverse events as a measure of safety and tolerability
時間枠:Screening, up to Day 10 of the follow-up period
|
Screening, up to Day 10 of the follow-up period
|
協力者と研究者
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
カナグリフロジン 300mgの臨床試験
-
Altavant Sciences GmbH完了肺動脈高血圧アメリカ, スペイン, イギリス, チェコ, セルビア, カナダ, ポーランド, イタリア, ボスニア・ヘルツェゴビナ, オーストリア, ドイツ, ベルギー, ブルガリア, フランス, ラトビア, モルドバ共和国, ウクライナ
-
Gamaleya Research Institute of Epidemiology and...まだ募集していませんグラム陰性菌感染症 | グラム陰性菌による菌血症 | グラム陰性肺炎
-
Johnson & Johnson Pharmaceutical Research & Development...引きこもった